SIRPA and neoplasm: For example, blockade of CD47-SIRPα or CD24-Siglec10 results in a macrophage-dependent reduction in tumor growth.11,12 Furthermore, developing additional therapies is essential to overcoming the limitations of ICI therapy, such as issues related to activating and recruiting immune cells in the TME.